Prescription Drug User Fee Act (PDUFA) action date is September 26, 2024
If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades
The application is supported by positive data from the EMERGENT clinical trial program showing KarXT is associated with significant improvements in schizophrenia symptoms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.